Inspired by in vitro data showing that si-CLU reduced the antioxidative stress capability and inhibited HNSCC cell viability under conditions of glucose deficiency, we further analyzed whether inhibiting CXCL8 signaling enhances the efficacy of anlotinib in suppressing HNSCC tumor growth. The gene discussed is CXCL8; the disease is head and neck squamous cell carcinoma.